je.st
news
Tag: longer
Custard creams no longer take the biscuit as sales crumble
2016-12-06 15:07:39| BBC News | Business | UK Edition
Sales of custard creams and digestive biscuits are crumbling as Britons opt for healthier and more indulgent treats.
Tags: sales
longer
biscuit
creams
Malaysian Grand Prix: Sepang to no longer host Formula 1 from 2018
2016-11-22 07:41:24| BBC News | Business | UK Edition
Malaysia will no longer host a Formula 1 grand prix after the current agreement expires in 2018.
Google quietly changed its privacy policy, no longer promises to anonymize your personal information when selling ads
2016-10-24 16:16:30| Extremetech
Google has removed language from its privacy policy in which it promised to keep customer data sandboxed and anonymous.
Tags: privacy
information
privacy policy
policy
iPhones No Longer Tethered in Some Apple Stores
2016-10-17 23:01:59| PC Magazine Cell Phones Product Guide
If you try to take off with one, an alarm will sound and Apple will brick the device.
Tags: stores
longer
apple
tethered
KEYTRUDA (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress
2016-10-09 08:15:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherapy (docetaxel) in patients with metastatic non-small cell lung cancer (NSCLC) previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1 (tumor proportion score [TPS] of one percent or more), as well as patients with high levels Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
longer
presented
cell
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »